Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | TNKS | O95271 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4054009 | 1.00 | GLA (0.77) | GLATDP1HDAC2MAPTHDAC1 | |
| Biphenyl SCHEMBL27860494 | 0.94 | GLA (0.88) | GLATDP1HDAC2MAPTHDAC1 | |
| Butenone SCHEMBL312972 | 0.87 | TDP1 (1.00) | GLATDP1HDAC2MAPTHDAC1 | |
| Butenone SCHEMBL12984182 | 0.87 | TDP1 (1.00) | GLATDP1HDAC2MAPTHDAC1 | |
| Butenone SCHEMBL76632 | 0.87 | TDP1 (1.00) | GLATDP1HDAC2MAPTHDAC1 | |
| Butenone SCHEMBL4306181 | 0.85 | TDP1 (0.95) | GLATDP1HDAC2MAPTHDAC1 | |
| Butenone SCHEMBL792625 | 0.85 | TDP1 (0.95) | GLATDP1HDAC2MAPTHDAC1 | |
| Butenone SCHEMBL14763524 | 0.85 | TDP1 (0.95) | GLATDP1HDAC2MAPTHDAC1 | |
| Butenone SCHEMBL7053850 | 0.85 | TDP1 (0.95) | GLATDP1HDAC2MAPTHDAC1 | |
| Butenone SCHEMBL6235457 | 0.85 | TDP1 (0.95) | GLATDP1HDAC2MAPTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3502109-A1 | TRIAZOLE-PHENYL-THIAZOLE HETEROCYCLES AS INNOVATIVE INHIBITORS OF TRYPANOTHIONE REDUCTASE AND THEIR USE AS LEISHMANICIDES | Consejo Superior De Investigaciones Científicas (ES) | 2019-06-26 | — | — | EP | disclosed |
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8507647-B2 | Antibacterial agents for the treatment of gram positive infections | CUBIST PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| WO-2009109504-A1 | ENOL CARBAMATE DERIVATIVES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-09-11 | — | — | WO | disclosed |
| US-7291743-B2 | Isoxazole derivatives and methods of treating nitric oxide mediated diseases | GENEBLUE CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-4393079-A | ANTIINFLAMMATORY AROMATIC KETONES | BEECHAM GROUP LIMITED (GB) | 1983-07-12 | — | — | US | disclosed |
| US-4262013-A | ANTILIPEMIC AGENTS | SANKYO COMPANY LIMITED (JP) | 1981-04-14 | — | — | US | disclosed |
| US-4216232-A | Pharmaceutical compositions | BEECHAM GROUP LIMITED (GB) | 1980-08-05 | — | — | US | disclosed |
| US-4198425-A | ANTILIPEMIC AGENTS | SANKYO COMPANY LIMITED (JP) | 1980-04-15 | — | — | US | disclosed |
| US-3950427-A | ANTIINFLAMMATORY, ANTIPYRETIC | BOEHRINGER INGELHEIM GMBH (DT) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | GLA 2579/4885TDP1 1761/4885HDAC2 910/4885 |
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | GLA 770/4885TDP1 4032/4885HDAC2 4198/4885 |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | GLA 2579/4885TDP1 1761/4885HDAC2 910/4885 |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | GLA 770/4885TDP1 4032/4885HDAC2 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.